aTYR PHARMA (ATYR) Interest & Investment Income (2015 - 2026)
aTYR PHARMA's (ATYR) quarterly Interest & Investment Income came in at $2000.0 in Q2 2026, up 122.22% on a YoY basis from $900.0 in Q2 2025, and up 103.23% quarter-over-quarter from -$62000.0 in Q1 2026.
Powered by 
Analysis
aTYR PHARMA (ATYR) Interest & Investment Income (2015 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has reported Interest & Investment Income for 12 consecutive years, with $2000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Interest & Investment Income rose 122.22% year-over-year to $2000.0; the trailing twelve-month figure through Jun 2026 stood at -$95000.0 (up 26.36% YoY), and the FY2021 full-year result was -$220000.0, changed N/A from the prior year.
- Interest & Investment Income grew to $2000.0 in Q2 2026 per ATYR's latest filing, from -$62000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $185000.0 in Q1 2023 and bottomed at -$496000.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged -$45000.0 across 5 years, with a median of -$26000.0 in 2025.
- The widest YoY moves for Interest & Investment Income: up 1862.5% in 2022, down 3442.86% in 2022.
- Over 5 years, Interest & Investment Income stood at $141000.0 in 2022, then tumbled by 160.28% to -$85000.0 in 2023, then soared by 88.24% to -$10000.0 in 2024, then increased by 10.0% to -$9000.0 in 2025, then surged by 122.22% to $2000.0 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $2000.0, -$62000.0, and -$9000.0 for Q2 2026, Q1 2026, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 120.60 Mn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | -48.00 Mn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | 67.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 48.00 Mn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | 36.92 Mn |
| 10 | aTYR PHARMA | 35.31 Mn | -22.30 Mn | - | 2,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2,000.00 |
| Mar 31, 2026 | -62,000.00 |
| Jun 30, 2025 | -9,000.00 |
| Mar 31, 2025 | -26,000.00 |
| Jun 30, 2024 | -10,000.00 |
| Mar 31, 2024 | -84,000.00 |
| Jun 30, 2023 | -85,000.00 |
| Mar 31, 2023 | 185,000.00 |
| Sep 30, 2022 | 141,000.00 |
| Jun 30, 2022 | -51,000.00 |
| Mar 31, 2022 | -496,000.00 |
| Dec 31, 2021 | -194,000.00 |
| Sep 30, 2021 | -8,000.00 |
| Jun 30, 2021 | -4,000.00 |
| Mar 31, 2021 | -14,000.00 |
| Jun 30, 2020 | 9,000.00 |
| Mar 31, 2020 | -13,000.00 |
| Jun 30, 2019 | 8,000.00 |
| Mar 31, 2019 | 20,000.00 |
| Dec 31, 2018 | -3,000.00 |